Kinase News and Research

RSS

Potential new treatment strategy against metastatic cancer cells

A team of scientists at The Scripps Research Institute has identified a potential treatment strategy against metastatic cancer cells that has never been tried before.

25 Oct 2004

Potential new protein marker for prognosis of breast and ovarian cancer

The researchers matched tumor samples to outcomes in about 100 patients diagnosed with either breast or ovarian cancer and found that a low level of Rab25 protein on a patient's cancer sample was associated with a better clinical outcome in both cancer types.

24 Oct 2004

Discovery of new protein involved in regulating the second most commonly mutated tumor suppressor in human tumors

Scientists in Tokyo have discovered a new protein, named PICT-1, that is involved in regulating PTEN, the second most commonly mutated tumor suppressor in human tumors.

22 Oct 2004

Lithium can protect the brain cells involved in learning and memory from radiation damage

Patients who undergo radiation for treatment of brain tumors may survive their cancer only to have lasting memory and learning deficiencies, the impact of which can be particularly devastating for children.

10 Oct 2004

Scientists have developed a new technology capable of improving survival outcomes after bone marrow transplantation

The study was published in the September issue of the prestigious medical journal, British Journal of Hematology. The technology involves the rational design and application of tyrosine kinase inhibitors for the treatment of leukemia, lymphoma, and graft versus host disease.

8 Oct 2004

Researchers reveal potential new role for Glivec/Imatinib

Imatinib – or Glivec as it also known – looks as if it may become an effective treatment for yet another type of cancer.

28 Sep 2004

Experimental drug PKC412 may be the key to treating myeloproliferative disease

Scientists at Dana-Farber Cancer Institute and Brigham and Women's Hospital have prolonged the lives of mice with a rare blood disorder by using an experimental drug that blocks signals promoting runaway growth of blood cells.

21 Sep 2004

HER-2 cell surface receptors tun on genes associated with carcinogenesis

Researchers at The University of Texas M. D. Anderson Cancer Center now have evidence that receptors found on tumors that were believed to function only on the surface of cells can actually switch on genes inside a cell's nucleus, thus promoting cancer development in two distinct ways.

21 Sep 2004

New anti-inflammatory strategy for cancer therapy

A new strategy for cancer therapy, which converts the tumor-promoting effect of the immune system’s inflammatory response into a cancer-killing outcome, is suggested in research findings by investigators at the University of California, San Diego (UCSD) School of Medicine.

20 Sep 2004

Tarceva plus Gemcitabine improves survival compared to Gemcitabine alone

OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche announced today that results from a randomized Phase III clinical study of the investigational drug Tarceva (erlotinib HCl), in combination with gemcitabine chemotherapy met its primary endpoint of improving survival.

20 Sep 2004

New method targeting hypermethylation detects ovarian cancer in the blood

Fox Chase Cancer Center researchers have found a new way to detect ovarian cancer in the blood. Reported in the Sept. 15, 2004, issue of Cancer Research, the new method targets hypermethylation--one mechanism used by cancer cells to turn off genes that protect against tumor development.

16 Sep 2004

Researchers accurately pinpoint the types of lymphoma, Hodgkins or non-Hodgkins

“There are many types and subtypes of lymphoma, some of which are easy to detect, but many that are very difficult to identify,” says Antonio Giordano, M.D., Ph.D., director of the Sbarro Institute at Temple and one of the study’s principal investigators.

1 Sep 2004

Enzyme activation key to body clock

Feel like time is repeating itself and won’t move on? It could be your internal clock is backpedaling because your PKG-II is out of whack.

20 Aug 2004

FDA fast tracks temsirolimus, first-line treatment of poor-prognosis patients with advanced renal cell carcinoma

Wyeth Pharmaceuticals has announced that the U.S. Food and Drug Administration has granted a new "fast track" designation for temsirolimus (CCI-779), an investigational mTOR kinase inhibitor, in the first-line treatment of poor-prognosis patients with advanced renal cell carcinoma (RCC).

18 Aug 2004

First evidence of the molecular link between inflammation and cancer

The investigators found that a gene called I-kappa-B kinase (IKK beta), a pro-inflammatory gene, acts differently in two cell types to cause cancer. When IKK beta was deleted, the cancer incidence and tumor growth in mice was decreased by nearly 80 percent.

5 Aug 2004

Scientists create mice that don't gain weight, even when fed fat-laden, high calorie diets

By altering the expression of a single -- albeit different – gene, Drs. Roger Davis (UMASS Medical School, USA) and Ying-Hue Lee (Academia Sinica, Taiwan) have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high calorie diets.

2 Aug 2004

Identification of PIK3CA as an oncogene associated with brain cancers opens the door to new screening processes

Hotspots in two areas of a gene that encodes a specific signaling enzyme, or kinase, are vulnerable to a variety of mutations found in five types of brain cancers, according to a report published in the August 1 issue of the journal Cancer Research.

2 Aug 2004

Proof of principle that it is possible to deliver new genes body-wide to all the muscles of an adult animal

MDA-supported researchers at the University of Washington-Seattle have delivered the gene for the dystrophin protein to all voluntary muscles with a single intravenous injection in mice with Duchenne muscular dystrophy (DMD).

29 Jul 2004

Epilepsy, new therapeutic possibilities

To date epilepsy research has mainly concentrated on the transmission of the nerve cell signals to what are known as the synapses.

23 Jul 2004

New compound that is designed to overcome Gleevec resistance

One of the truly spectacular success stories in modern oncology is the development and implementation of Gleevec, a drug that virtually halts the progress of chronic myeloid leukemia. Yet for some patients who harbor particularly stubborn genetic mutations, Gleevec fails miserably.

17 Jul 2004